RAPID ANALYSIS OF RILPIVIRINE, EMTRICITABINE AND TENOFOVIR ACTIVE INGREDIENTS BY NOVEL HPLC METHOD RİLPİVİRİN, EMTRİSİTABİN VE TENOFOVİR AKTİF BİLEŞENLERİNİN YENİ HPLC YÖNTEMİYLE HIZLI ANALİZİ


Creative Commons License

BAY M., Genc A. A., Bouali W., TIRIS G., ERK N.

Ankara Universitesi Eczacilik Fakultesi Dergisi, vol.50, no.1, pp.79-87, 2026 (Scopus, TRDizin) identifier

  • Publication Type: Article / Article
  • Volume: 50 Issue: 1
  • Publication Date: 2026
  • Doi Number: 10.33483/jfpau.1632572
  • Journal Name: Ankara Universitesi Eczacilik Fakultesi Dergisi
  • Journal Indexes: Scopus, Central & Eastern European Academic Source (CEEAS), TR DİZİN (ULAKBİM)
  • Page Numbers: pp.79-87
  • Keywords: Emtricitabine, rilpivirine, RP-HPLC, simultaneous determination, tenofovir
  • Bezmialem Vakıf University Affiliated: Yes

Abstract

Objective: A novel high-performance liquid chromatography (HPLC) method was developed for the simultaneous determination of Emtricitabine (EMT), Tenofovir (TNF), and Rilpivirine (RLP). Material and Method: The analysis was performed using a Waters XBridge C18 (3.5 µm, 4.6 × 150 mm) column. The mobile phase consisted of methanol and triethylamine buffer (pH 3.15) in a 60:40 (v/v) ratio, with a flow rate of 1.2 ml/min. The developed method was successfully applied to standard mixtures and pharmaceutical tablet formulations containing EMT, TNF, and RLP, without matrix interference. Result and Discussion: The proposed technique exhibited good linearity, with correlation coefficients (R²) of 0.999 for EMT, 0.999 for TNF, and 1.000 for RLP. The calibration ranges were 10.0–600.0 µg/ml for EMT, 2.0–75.0 µg/ml for TNF, and 2.0–75.0 µg/ml for RLP. The method was validated in accordance with ICH guidelines, demonstrating high sensitivity, precision, and accuracy. It was found to be a rapid, economical, and efficient approach for the simultaneous determination of these active pharmaceutical ingredients.